Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

The liver scarring of α1-antitrypsin deficiency, the most common genetic cause for which children undergo liver transplantation, might be reversed or prevented with a medication that has long been used to treat seizures, according to findings from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine that will published in Science and are available online today through the Science Express website.

4 Jun 2010

American Cancer Society and NPCRC award $1.8M for palliative care research

The American Cancer Society and the National Palliative Care Research Center (NPCRC) are awarding $1.8 million in research grants to researchers at 12 institutions for studies aimed at reducing suffering for seriously ill patients and their family caregivers. The studies will be conducted over the next two years. Since 2007, a collaborative effort by the organizations has awarded 51 grants totaling almost $7 million.

4 Jun 2010

New UNC-Olympus Research Imaging Center opens doors

The University of North Carolina (UNC) at Chapel Hill today opened the doors of a new facility designed to be one of the world's most sophisticated research centers devoted to life science imaging. The new UNC-Olympus Research Imaging Center provides researchers with advanced microscopes and camera equipment, software, consultation and expertise, in an environment intended to encourage the highest levels of scientific inquiry.

From Evident Corporation - Life Sciences 4 Jun 2010

Special dementia care plan does not slow functional decline compared with usual care: Study

A special dementia care plan, involving regular assessments of patients with Alzheimer's disease in specialist memory clinics, does not slow functional decline compared with usual care, finds a study published on bmj.com today.

4 Jun 2010

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced today that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer's disease (AD) and related disorders are currently being diagnosed and treated.

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

Nutrient found in maternal diet provide lasting cognitive, emotional benefits to people with Down syndrome: Study

A nutrient found in egg yolks, liver and cauliflower taken by mothers during pregnancy and nursing may offer lifelong "dramatic" health benefits to people with Down syndrome.

4 Jun 2010

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences Ltd. and Pan-Provincial Vaccine Enterprise Inc. of Saskatoon, Saskatchewan, today announced that the two groups have entered into a licensing agreement granting PREVENT exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis vaccines.

3 Jun 2010

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Cure Alzheimer's Fund recently awarded the University of Texas Health Science Center at Houston and the University of Houston a $150,000 grant to fund innovative research on Alzheimer's disease, which currently affects 5.3 million Americans and their families and is the most common cause of dementia in the elderly.

3 Jun 2010

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Q Therapeutics, Inc. announced today that Piotr Walczak, M.D., of Johns Hopkins University has received notification of a $1,000,000 grant to be awarded by the Maryland Stem Cell Research Fund (MSCRF) which will enable further study of Q's human neural glial cell product Q-Cells® in preclinical models of demyelinating disease.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.

2 Jun 2010

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.

2 Jun 2010

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

The majority of Australians (58%) are worried about their brain health and the threat of age-related degenerative brain disease, according to a new survey. The national survey was commissioned by leading medical research institute Neuroscience Research Australia and polled 1000 Australians aged 18 to over 75.

2 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

Amorfix provides update on development of blood test for vCJD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, provides an update on the development of a blood test for vCJD, one of its six product development programs.

31 May 2010

Education slows down development of dementia: Researchers

Researchers have discovered that education not only delays the early symptoms of dementia, but can also slow down the development of the disease - a finding that could result in faster diagnosis and treatment of dementia, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

31 May 2010

Deep-brain stimulation makes difference in the lives of people with Parkinson disease

A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.

31 May 2010

Alzheimer's disease awareness event aims to raise over $100,000 for Alzheimer Society of Montreal

It's on a path full of history and collective memories that more than 500 walkers will gather, on Sunday, May 30th, for the fourth edition of the RONA Walk for Memories. This Alzheimer's disease awareness event, which will take place on the Quays of the Old Port and in the streets of the Old Montreal, aims to raise over $100,000 for the Alzheimer Society of Montreal!

31 May 2010

Circumstantial evidence suggests first identified Alzheimer disease patient carried N141I presenilin-2 mutation

Writing the latest pages of an anthropological mystery, scientists propose in this month's Archives of Neurology that it is highly possible that Auguste Deter, the first identified Alzheimer disease patient, carried the N141I presenilin-2 mutation—the same one as in present-day U.S. families descended from German emigrants who settled near the river Volga in Russia.

29 May 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

American Cancer Society and NPCRC award $1.8M for palliative care research

New UNC-Olympus Research Imaging Center opens doors

Special dementia care plan does not slow functional decline compared with usual care: Study

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Nutrient found in maternal diet provide lasting cognitive, emotional benefits to people with Down syndrome: Study

Amorfix Life Sciences signs licensing agreement with PREVENT

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

Amorfix provides update on development of blood test for vCJD

Education slows down development of dementia: Researchers

Deep-brain stimulation makes difference in the lives of people with Parkinson disease

Alzheimer's disease awareness event aims to raise over $100,000 for Alzheimer Society of Montreal

Circumstantial evidence suggests first identified Alzheimer disease patient carried N141I presenilin-2 mutation

eBook: Hallmarks of Neurodegeneration eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

eBook: Hallmarks of Neurodegeneration eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in